Literature DB >> 21491159

The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human type 1 diabetes mellitus).

E Peschke1, K Hofmann, I Bähr, S Streck, E Albrecht, D Wedekind, E Mühlbauer.   

Abstract

AIMS/HYPOTHESIS: It is well documented that melatonin influences insulin secretion mediated by G-protein-coupled melatonin receptor isoforms MT1 and MT2, which are present in rat and human pancreatic islets, as well as in rat insulinoma cells. Recent investigations have proven that hyperinsulinaemic Goto-Kakizaki (GK) rats, which are a rat model of type 2 diabetic rats, and humans have decreased melatonin plasma levels, whereas a streptozotocin-induced rat model of diabetes developed reduced insulin levels combined with increased melatonin levels.
METHODS: Plasma levels of glucose, insulin and melatonin as well as RNA expression of pineal Aanat, Hiomt (also known as Asmt), insulin receptor, adrenoceptor β1 and the clock genes Per1 and Bmal1 (also known as Arntl) were determined in male and female LEW.1AR1-iddm rats as well as in insulin-substituted LEW.1AR1-iddm rats.
RESULTS: Severe hypoinsulinaemia in diabetic LEW.1AR1-iddm rats was associated with decreased body weight and increased melatonin plasma levels combined with mainly elevated expression of Aanat, Hiomt, pineal insulin receptor and adrenoceptor β1. The changes were normalised by insulin substitution. Diurnal profiles of plasma melatonin and of antagonistic clock genes Per1 and Bmal1 were maintained in diabetic and insulin-substituted rats. CONCLUSIONS/
INTERPRETATION: The assumed causal relation between elevated melatonin and reduced insulin levels in LEW.1AR1-iddm rats is supported by the observation that insulin substitution normalised these changes. Further support for this interpretation comes from the observation that in GK rats an increase of plasma insulin was combined with a decrease of plasma noradrenaline (norepinephrine), the most important activator of melatonin synthesis. These relationships between the noradrenergic and insulin pathway support the existence of melatonin-insulin antagonism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21491159     DOI: 10.1007/s00125-011-2138-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  49 in total

1.  Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus.

Authors:  F Damiola; N Le Minh; N Preitner; B Kornmann; F Fleury-Olela; U Schibler
Journal:  Genes Dev       Date:  2000-12-01       Impact factor: 11.361

2.  Melatonin stimulates inositol-1,4,5-trisphosphate and Ca2+ release from INS1 insulinoma cells.

Authors:  Andreas G Bach; Sabine Wolgast; Eckhard Mühlbauer; Elmar Peschke
Journal:  J Pineal Res       Date:  2005-10       Impact factor: 13.007

3.  Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity.

Authors:  Shigeru Nishida; Toshiko Segawa; Ichiro Murai; Shigeki Nakagawa
Journal:  J Pineal Res       Date:  2002-01       Impact factor: 13.007

4.  Evidence for a melatonin receptor within pancreatic islets of neonate rats: functional, autoradiographic, and molecular investigations.

Authors:  E Peschke; J D Fauteck; U Musshoff; F Schmidt; A Beckmann; D Peschke
Journal:  J Pineal Res       Date:  2000-04       Impact factor: 13.007

Review 5.  Metabolic effects of melatonin on oxidative stress and diabetes mellitus.

Authors:  Shigeru Nishida
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

6.  Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status.

Authors:  Elmar Peschke; Thomas Frese; Erik Chankiewitz; Dorothee Peschke; Uwe Preiss; Ulrich Schneyer; Rainer Spessert; Eckhard Mühlbauer
Journal:  J Pineal Res       Date:  2006-03       Impact factor: 13.007

7.  Modulation of the cGMP signaling pathway by melatonin in pancreatic beta-cells.

Authors:  Ina Stumpf; Ivonne Bazwinsky; Elmar Peschke
Journal:  J Pineal Res       Date:  2008-10-08       Impact factor: 13.007

8.  Indication of circadian oscillations in the rat pancreas.

Authors:  E Mühlbauer; S Wolgast; U Finckh; D Peschke; E Peschke
Journal:  FEBS Lett       Date:  2004-04-23       Impact factor: 4.124

9.  Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses.

Authors:  S M Reppert; D R Weaver; T Ebisawa
Journal:  Neuron       Date:  1994-11       Impact factor: 17.173

10.  Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1.

Authors:  Elmar Peschke; Eckhard Mühlbauer; Ulrich Musshoff; Valer J Csernus; Erik Chankiewitz; Dorothee Peschke
Journal:  J Pineal Res       Date:  2002-09       Impact factor: 13.007

View more
  5 in total

1.  The use of animal models in diabetes research.

Authors:  Aileen J F King
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Human and Rodent Cell Lines as Models of Functional Melatonin-Responsive Pancreatic Islet Cells.

Authors:  Juliane Zibolka; Ina Bähr; Elmar Peschke; Eckhard Mühlbauer; Ivonne Bazwinsky-Wutschke
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Melatonin: buffering the immune system.

Authors:  Antonio Carrillo-Vico; Patricia J Lardone; Nuria Alvarez-Sánchez; Ana Rodríguez-Rodríguez; Juan M Guerrero
Journal:  Int J Mol Sci       Date:  2013-04-22       Impact factor: 5.923

Review 4.  Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon.

Authors:  Elmar Peschke; Ina Bähr; Eckhard Mühlbauer
Journal:  Int J Mol Sci       Date:  2013-03-27       Impact factor: 5.923

5.  Effects of Streptozotocin-Induced Diabetes on the Pineal Gland in the Domestic Pig.

Authors:  Bogdan Lewczuk; Magdalena Prusik; Natalia Ziółkowska; Michał Dąbrowski; Kamila Martniuk; Maria Hanuszewska; Łukasz Zielonka
Journal:  Int J Mol Sci       Date:  2018-10-09       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.